Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volrustomig (MEDI5752) monotherapy in recurrent or metastatic cervical cancer
CTR20242629Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of volrustomig in cervical cancer (mCC), sponsored by AstraZeneca. Started Sep 2024; status: active.
02
Drugs
volrustomig
03
Conditions
cervical cancer (mCC)
Beyond the preview
Go deeper on CTR20242629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242629.